Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK allergy drugs

This article was originally published in The Tan Sheet

Executive Summary

Committee on Safety of Medicines proposes lifting Rx restrictions to allow pharmacy sale of azelastine hydrochloride eye drops (Asta's Rx Optivar in the U.S.) for "treatment of seasonal and perennial allergic conjunctivitis in adults and children" ages 12 and older, according to Jan. 22 consultation letter. CSM also invites comments on proposal to allow pharmacy sale of fluticasone proprionate (GlaxoSmithKline's Flonase in the U.S.) non-pressurized nasal spray for prevention and treatment of allergic rhinitis in persons 18 and older...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts